Recent news releases
-
Aug 12, 2026 Apotex Announces First Quarter 2027 Results
-
Jul 17, 2026 Apotex Receives Investment Grade Issuer Rating from Morningstar DBRS and Announces Amended & Restated Credit Agreement
-
Jul 8, 2026 Apotex expands U.S. hospital portfolio with launch of generic Infuvite® Adult and Pediatric Injection
-
Jul 1, 2026 Apotex completes previously announced strategic transaction with Cumberland Pharmaceuticals
-
Jun 3, 2026 Apotex launches sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, eligible for 180-day shared exclusivity
-
Apr 27, 2026 Apotex Announces FDA Approval of Generic Infuvite® Pediatric Injection, Eligible for 180 day CGT Exclusivity (Single Dose Vial) Complementing its Recent Approval of Generic Infuvite Adult Injection
-
Apr 23, 2026 Apotex Announces Strategic Transaction with Cumberland Pharmaceuticals to Integrate their U.S. Branded Businesses
-
Apr 14, 2026 Apotex Announces Strategic U.S. Sterile Filling Partnership with Halo Pharmaceuticals
-
Apr 14, 2026 Apotex Announces FDA Approval of First Generic Infuvite® Adult Injection (Single Dose Vial and Pharmacy Bulk package) with 180 Day CGT Exclusivity for the Pharmacy bulk package in Partnership with Orbicular and Gland Pharma
-
Apr 10, 2026 Apotex Receives First U.S. FDA Tentative Approval for a Generic Version of Ozempic® (Semaglutide Injection) in Partnership with Orbicular